Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism

Diabetes(2025)10.2337/db24-0861Source: DataRank Database

The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism is a research paper published in Diabetes (2025). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

9 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 6.84)OA: closedTopics (33)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Xilal Y. Rima ORCID,David Bradley ORCID,Joey Z. Liu,Valerie P. Wright ORCID,ANASTASIIA AMARI

Live enrichment

PubMed:40663700 OpenAlex:https://openalex.org/W4412434056

Clinical Center

Grant: KL2TR001068

Clinical Center

Grant: HL135622

American Heart Association

Grant: 24PRE1243747

National Heart, Lung, and Blood Institute

Grant: 5T32HL149637

Burroughs Wellcome Fund

Grant: 1285320

American Diabetes Association

Grant: 1-16-ICTS-049

FWCI

6.84

Citation Percentile

1.0%

Citation Trend

2026

closedLicense: https://www.diabetesjournals.org/journals/pages/license

publisherhttps://diabetesjournals.org/diabetes/article-pdf/74/9/1512/837291/db240861.pdf

journalhttps://doi.org/10.2337/db24-0861

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40663700

Fields of Study

Liver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementDiet and metabolism studies

MeSH Terms

Glucagon-Like Peptide-1 Receptor AgonistsAnimalsGlucagon-Like PeptidesFatty LiverHumansHypoglycemic AgentsImmunoglobulin Fc FragmentsLiverObesityRecombinant Fusion ProteinsWeight Loss

Keywords

SteatosisInternal medicineEndocrinologyMedicineDulaglutideLipogenesisGlucagon-like peptide 1 receptorLiraglutideExenatideFatty liverWeight lossInsulin resistanceAdipose tissueDiabetes mellitusType 2 diabetesAgonistReceptorObesityDisease

Sustainable Development Goals

SDG 0: Good health and well-being

The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism

FAIR Checklist

Authors (14)

Funding (6 grants)

Impact

Open Access

Topics